Lipocine (NASDAQ:LPCN) Price Target Lowered to $7.00 at HC Wainwright

Lipocine (NASDAQ:LPCN) had its price objective lowered by HC Wainwright from $8.00 to $7.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lipocine in a report on Tuesday. Alliance Global Partners raised shares of Lipocine to a “strong-buy” rating in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Lipocine Trading Down 3.4%

LPCN opened at $2.82 on Thursday. Lipocine has a twelve month low of $2.52 and a twelve month high of $5.50. The firm has a market capitalization of $15.66 million, a PE ratio of -3.24 and a beta of 1.25. The firm’s 50-day moving average price is $2.89 and its 200 day moving average price is $3.10.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 6th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.24 million.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.